openPR Logo
Press release

Idiopathic Pulmonary Fibrosis Market - Rise in Geriatric Population and Surge in Cigarette Smoking Population Boost the Market Growth

02-21-2019 10:05 AM CET | Health & Medicine

Press release from: Allied Market Research

Idiopathic Pulmonary Fibrosis Market

Idiopathic Pulmonary Fibrosis Market

The Idiopathic Pulmonary Fibrosis Market is expected to grow at an average annual rate of 11.9% from 2013 to 2023, reaching $ 3,569 million by 2023. Perifenidone occupied more than half of the entire market in 2016.

Idiopathic pulmonary fibrosis is a disease in which pulmonary tissue becomes thicker and harder over time, decreasing the ability of the tissue to carry oxygen. The increase in the elderly population and the increase in patients suffering from idiopathic pulmonary fibrosis are expected to stimulate market growth. In addition, the growth of cigarette smoking increases the growth of the market. However, if treatment options that can completely cure the disease become unavailable, market growth will be limited.

Download PDF Report Sample @

Perifenidone is expected to dominate the market throughout the analysis period as it helps slow the scarring and preserve lung function. Nintedanib is expected to grow at a CAGR of 12.2% over the forecast period.
Asia Pacific is expected to record a high CAGR of 13.0% over the forecast period due to population growth and aging populations suffering from fibrotic diseases. In addition, increased spending on health provides an opportunity for market growth.

The major companies profiled in the report include
• MediciNova Inc.
• Boehringer Ingelheim
• F. Hoffmann-La Roche
• FibroGen Inc.
• Promedior Inc.
• Merck & Co. Inc.
• Galapagos NV
• Biogen
• Bristol-Myers Squibb Company
• Prometic Life Sciences Inc.
• Cipla Inc.

Make an Enquiry before Buy @

Key Findings of the Idiopathic Pulmonary Fibrosis Market:
• Nintedanib is projected to grow at a CAGR of 12.2% during the forecast period.
• Pirfenidone accounted for more than half of the share of the global idiopathic pulmonary fibrosis market in 2016.
• France and Germany collectively contributed for more than one-third share of the European idiopathic pulmonary fibrosis market in 2016.
• Japan was the major shareholder in 2016, accounting for more than one-third share of the Asia-Pacific idiopathic pulmonary fibrosis market.
• Brazil is the major shareholder in 2016, accounting for nearly than one-fourth share of the LAMEA idiopathic pulmonary fibrosis market.

Access Full Summery @

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.


David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Idiopathic Pulmonary Fibrosis Market - Rise in Geriatric Population and Surge in Cigarette Smoking Population Boost the Market Growth here

News-ID: 1606174 • Views: 251

More Releases from Allied Market Research

North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ Synthetic biology is at a nascent stage and has recently

All 5 Releases

More Releases for Idiopathic

Chronic Idiopathic Constipation (CIC) Treatment Market - Regional Analysis
Regional segmentation of chronic idiopathic constipation treatment market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America chronic idiopathic constipation treatment market holds dominant position owing to high percentage of population suffering from chronic constipation. For instance, according to European Journal of Pharmacology, 2017, in the U.S. 12%–19% of population suffers from chronic constipation. This is expected to aid in growth
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ As per the findings of research, it
Juvenile Idiopathic Arthritis Therapeutics Market
JIA is also known as juvenile idiopathic arthritis and is the most common inflammatory arthritis of childhood, musculoskeletal pain is a common symptom in childhood and is usually benign and self-resolving. JIA is affected to children who are under age 17. Recognizing rare but treatable causes, including inflammatory, malignant and infectious etiologies, remains a constant challenge. According to the American College of Rheumatology, Juvenile idiopathic arthritis affects one in 1000
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline …
ReportsWorldwide has announced the addition of a new report title Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H2 2017, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) (Hematological Disorders) pipeline landscape. Idiopathic thrombocytopenic purpura is a bleeding
Idiopathic Short Stature - Pipeline Insight Market Research Report, 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Idiopathic Short Stature - Pipeline Insight, 2017”. This report provides comprehensive insights of the ongoing therapeutic research and development across Idiopathic Short Stature. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. Request For Sample Report@ A comparative pipeline therapeutics assessment of Idiopathic Short Stature
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation